MiNK Therapeutics, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. MiNK is a clinical-stage biotechnology company developing allogeneic iNKT cell therapies; it reported operating expenses and losses, with no revenue reported in the statements provided.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 / prior date |
|---|---|---|
| Research and development expense | $4.19 million | $5.28 million |
| General and administrative expense | $1.66 million | $2.10 million |
| Operating loss | $5.85 million | $7.37 million |
| Net loss | $5.69 million | $7.78 million |
| Basic and diluted loss per share | $0.17 | $0.23 |
| Net cash used in operating activities | $4.37 million | $4.20 million |
| Cash and cash equivalents | $14.89 million | $19.64 million at Dec. 31, 2022 |
- Operating expenses totaled $5.85 million; revenue-based margins are not meaningful because no revenue is reported.
- Current assets were $15.52 million and current liabilities $11.25 million, implying working capital of about $4.27 million. Total liabilities included $9.72 million due to related parties; the filing does not identify this balance as conventional debt.
- Accumulated deficit was $116.6 million. Stockholders’ deficit was $4.48 million. No revenue, profitability, or operating cash-flow guidance was provided.
Changes and operating developments
- Year-over-year R&D and G&A expenses each declined about 21%. Management attributed the decreases mainly to clinical-trial timing, lower allocated Agenus services, and lower professional fees; increased personnel costs partly offset the reductions.
- Net loss narrowed by about 27%, while operating cash use increased from $4.20 million to $4.37 million. Cash fell by $4.74 million during the quarter.
- Management highlighted agenT-797 Phase 1 activity in solid tumors, including a reported ongoing partial response in a gastric cancer patient receiving the drug with nivolumab. It plans to further evaluate signals in a Phase 1/2 expansion trial in relapsed/refractory gastric cancer.
- MiNK-215 and MiNK-413 remain preclinical; IND-enabling activities were planned for 2023. Management described strategic partnering discussions for viral ARDS and the BCMA program as underway.
Outlook, risks, and unusual items
- MiNK expects continuing operating losses and negative cash flows. Management said March 31 cash should fund requirements for more than one year from issuance of the financial statements, with spending to be adjusted to preserve liquidity.
- Potential funding sources include collaborations, out-licensing or partnerships, debt, or equity issuance. Agenus indicated willingness to provide certain loans if other funding is unavailable; Agenus agreed not to require repayment of the $9.72 million related-party balance before June 30, 2024.
- A Walloon Region default judgment seeks repayment of approximately €2.09 million of an advance. MiNK recorded approximately $2.3 million in other current liabilities and continues to evaluate its options. The company previously reduced the recorded liability and recognized a gain in 2022.
- Clinical development, regulatory approval, trial costs, and the timing of potential partnering or cash inflows remain uncertain. The filing reported no material changes to the risk factors in the 2022 Form 10-K and no material legal proceedings. Disclosure controls were reported effective.
Important facts for investors to verify
- Cash runway assumptions and actual quarterly cash burn, given cash declined to $14.89 million.
- Terms, availability, and repayment treatment of Agenus-related funding and services.
- Status and potential financial impact of the Walloon Region judgment and recorded liability.
- Clinical-trial progress and the evidence supporting reported agenT-797 activity and safety.
- Timing and funding needs for planned trials and preclinical programs, and prospects for external partnerships or financing.